Volume | 40,461 |
|
|||||
News | - | ||||||
Day High | 2.15 | Low High |
|||||
Day Low | 2.04 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Revelation Biosciences Inc | REVB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.14 | 2.04 | 2.15 | 2.09 | 2.07 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
270 | 40,461 | $ 2.09 | $ 84,397 | - | 1.7801 - 39.30 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:28:51 | formt | 929 | $ 2.05 | USD |
Revelation Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.1k | 209.91k | - | 0 | -120k | -0.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Revelation Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REVB Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.92 | 2.38 | 1.8801 | 2.17 | 62,656 | 0.13 | 6.77% |
1 Month | 2.60 | 2.96 | 1.7801 | 2.40 | 66,597 | -0.55 | -21.15% |
3 Months | 9.12 | 11.90 | 1.7801 | 3.65 | 322,166 | -7.07 | -77.52% |
6 Months | 18.915 | 25.26 | 1.7801 | 7.91 | 273,538 | -16.87 | -89.16% |
1 Year | 33.30 | 39.30 | 1.7801 | 16.57 | 222,455 | -31.25 | -93.84% |
3 Years | 8,799.00 | 10,237.50 | 1.7801 | 983.10 | 1,284,928 | -8,796.95 | -99.98% |
5 Years | 8,799.00 | 10,237.50 | 1.7801 | 983.10 | 1,284,928 | -8,796.95 | -99.98% |
Revelation Biosciences Description
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. |